PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27Kip1 axis

Abstract Background Altered glucose metabolism endows tumor cells with metabolic flexibility for biosynthesis requirements. Phosphoenolpyruvate carboxykinase 1 (PCK1), a key enzyme in the gluconeogenesis pathway, is downregulated in hepatocellular carcinoma (HCC) and predicts poor prognosis. Overexp...

Full description

Bibliographic Details
Main Authors: Lin Tuo, Jin Xiang, Xuanming Pan, Jieli Hu, Hua Tang, Li Liang, Jie Xia, Yuan Hu, Wenlu Zhang, Ailong Huang, Kai Wang, Ni Tang
Format: Article
Language:English
Published: BMC 2019-02-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13046-019-1029-y
id doaj-098f549e562440f1980394c9d9c3365b
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Lin Tuo
Jin Xiang
Xuanming Pan
Jieli Hu
Hua Tang
Li Liang
Jie Xia
Yuan Hu
Wenlu Zhang
Ailong Huang
Kai Wang
Ni Tang
spellingShingle Lin Tuo
Jin Xiang
Xuanming Pan
Jieli Hu
Hua Tang
Li Liang
Jie Xia
Yuan Hu
Wenlu Zhang
Ailong Huang
Kai Wang
Ni Tang
PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27Kip1 axis
Journal of Experimental & Clinical Cancer Research
Phosphoenolpyruvate carboxykinase 1
Hepatocellular carcinoma
Cell cycle arrest
CDK/Rb/E2F pathway
AMP-activated protein kinase
author_facet Lin Tuo
Jin Xiang
Xuanming Pan
Jieli Hu
Hua Tang
Li Liang
Jie Xia
Yuan Hu
Wenlu Zhang
Ailong Huang
Kai Wang
Ni Tang
author_sort Lin Tuo
title PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27Kip1 axis
title_short PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27Kip1 axis
title_full PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27Kip1 axis
title_fullStr PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27Kip1 axis
title_full_unstemmed PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27Kip1 axis
title_sort pck1 negatively regulates cell cycle progression and hepatoma cell proliferation via the ampk/p27kip1 axis
publisher BMC
series Journal of Experimental & Clinical Cancer Research
issn 1756-9966
publishDate 2019-02-01
description Abstract Background Altered glucose metabolism endows tumor cells with metabolic flexibility for biosynthesis requirements. Phosphoenolpyruvate carboxykinase 1 (PCK1), a key enzyme in the gluconeogenesis pathway, is downregulated in hepatocellular carcinoma (HCC) and predicts poor prognosis. Overexpression of PCK1 has been shown to suppress liver tumor growth, but the underlying mechanism remains unclear. Methods mRNA and protein expression patterns of PCK1, AMPK, pAMPK, and the CDK/Rb/E2F pathway were determined using qRT-PCR and western blotting. Cell proliferation ability and cell cycle were assessed by MTS assay and flow cytometric analysis. The effect of PCK1 on tumor growth was examined in xenograft implantation models. Results Both gain and loss-of-function experiments demonstrated that PCK1 deficiency promotes hepatoma cell proliferation through inactivation of AMPK, suppression of p27Kip1 expression, and stimulation of the CDK/Rb/E2F pathway, thereby accelerating cell cycle transition from the G1 to S phase under glucose-starved conditions. Overexpression of PCK1 reduced cellular ATP levels and enhanced AMPK phosphorylation and p27Kip1 expression but decreased Rb phosphorylation, leading to cell cycle arrest at G1. AMPK knockdown significantly reversed G1-phase arrest and growth inhibition of PCK1-expressing SK-Hep1 cells. In addition, the AMPK activator metformin remarkably suppressed the growth of PCK1-knockout PLC/PRF/5 cells and inhibited tumor growth in an orthotropic HCC mouse model. Conclusion This study revealed that PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27Kip1 axis and supports a potential therapeutic and protective effect of metformin on HCC.
topic Phosphoenolpyruvate carboxykinase 1
Hepatocellular carcinoma
Cell cycle arrest
CDK/Rb/E2F pathway
AMP-activated protein kinase
url http://link.springer.com/article/10.1186/s13046-019-1029-y
work_keys_str_mv AT lintuo pck1negativelyregulatescellcycleprogressionandhepatomacellproliferationviatheampkp27kip1axis
AT jinxiang pck1negativelyregulatescellcycleprogressionandhepatomacellproliferationviatheampkp27kip1axis
AT xuanmingpan pck1negativelyregulatescellcycleprogressionandhepatomacellproliferationviatheampkp27kip1axis
AT jielihu pck1negativelyregulatescellcycleprogressionandhepatomacellproliferationviatheampkp27kip1axis
AT huatang pck1negativelyregulatescellcycleprogressionandhepatomacellproliferationviatheampkp27kip1axis
AT liliang pck1negativelyregulatescellcycleprogressionandhepatomacellproliferationviatheampkp27kip1axis
AT jiexia pck1negativelyregulatescellcycleprogressionandhepatomacellproliferationviatheampkp27kip1axis
AT yuanhu pck1negativelyregulatescellcycleprogressionandhepatomacellproliferationviatheampkp27kip1axis
AT wenluzhang pck1negativelyregulatescellcycleprogressionandhepatomacellproliferationviatheampkp27kip1axis
AT ailonghuang pck1negativelyregulatescellcycleprogressionandhepatomacellproliferationviatheampkp27kip1axis
AT kaiwang pck1negativelyregulatescellcycleprogressionandhepatomacellproliferationviatheampkp27kip1axis
AT nitang pck1negativelyregulatescellcycleprogressionandhepatomacellproliferationviatheampkp27kip1axis
_version_ 1724841655272472576
spelling doaj-098f549e562440f1980394c9d9c3365b2020-11-25T02:27:39ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662019-02-0138111610.1186/s13046-019-1029-yPCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27Kip1 axisLin Tuo0Jin Xiang1Xuanming Pan2Jieli Hu3Hua Tang4Li Liang5Jie Xia6Yuan Hu7Wenlu Zhang8Ailong Huang9Kai Wang10Ni Tang11Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical UniversityKey Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical UniversityKey Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical UniversityKey Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical UniversityKey Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical UniversityKey Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical UniversityKey Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical UniversityKey Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical UniversityKey Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical UniversityKey Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical UniversityKey Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical UniversityKey Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical UniversityAbstract Background Altered glucose metabolism endows tumor cells with metabolic flexibility for biosynthesis requirements. Phosphoenolpyruvate carboxykinase 1 (PCK1), a key enzyme in the gluconeogenesis pathway, is downregulated in hepatocellular carcinoma (HCC) and predicts poor prognosis. Overexpression of PCK1 has been shown to suppress liver tumor growth, but the underlying mechanism remains unclear. Methods mRNA and protein expression patterns of PCK1, AMPK, pAMPK, and the CDK/Rb/E2F pathway were determined using qRT-PCR and western blotting. Cell proliferation ability and cell cycle were assessed by MTS assay and flow cytometric analysis. The effect of PCK1 on tumor growth was examined in xenograft implantation models. Results Both gain and loss-of-function experiments demonstrated that PCK1 deficiency promotes hepatoma cell proliferation through inactivation of AMPK, suppression of p27Kip1 expression, and stimulation of the CDK/Rb/E2F pathway, thereby accelerating cell cycle transition from the G1 to S phase under glucose-starved conditions. Overexpression of PCK1 reduced cellular ATP levels and enhanced AMPK phosphorylation and p27Kip1 expression but decreased Rb phosphorylation, leading to cell cycle arrest at G1. AMPK knockdown significantly reversed G1-phase arrest and growth inhibition of PCK1-expressing SK-Hep1 cells. In addition, the AMPK activator metformin remarkably suppressed the growth of PCK1-knockout PLC/PRF/5 cells and inhibited tumor growth in an orthotropic HCC mouse model. Conclusion This study revealed that PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27Kip1 axis and supports a potential therapeutic and protective effect of metformin on HCC.http://link.springer.com/article/10.1186/s13046-019-1029-yPhosphoenolpyruvate carboxykinase 1Hepatocellular carcinomaCell cycle arrestCDK/Rb/E2F pathwayAMP-activated protein kinase